Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    Hereditary Breast and Ovarian Cancer | United States, Georgia
Show Display Options
Rank Status Study
1 Active, not recruiting Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
Conditions: Adult Solid Neoplasm;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study

Indicates status has not been verified in more than two years